Last updated: September 9, 2026
Thallous chloride Tl-201 is a mature diagnostic radiopharmaceutical used primarily for myocardial perfusion imaging and, in limited settings, parathyroid localization. Its commercial position is shaped by declining use of thallium-based SPECT, competition from technetium-99m agents and cardiac PET, isotope-production constraints, and the absence of meaningful remaining patent exclusivity. No public company reports standalone Tl-201 revenue, so the product’s financial trajectory must be assessed through procedure volume, reimbursement, supplier activity, and substitution trends.
What is thallous chloride Tl-201 used for?
Thallous chloride Tl-201 is an injectable radioactive diagnostic agent containing thallium-201 chloride. FDA labeling identifies myocardial perfusion imaging as its principal use, including assessment of regional myocardial perfusion and identification of ischemic or infarcted tissue. It has also been used for parathyroid imaging in selected cases.[1]
Thallium-201 has a physical half-life of approximately 73 hours. It emits low-energy X-rays and gamma radiation suitable for SPECT imaging. The relatively long half-life permits redistribution imaging but creates higher radiation exposure and lower image quality than many technetium-based alternatives.[1,2]
| Attribute |
Thallous chloride Tl-201 |
| Active isotope |
Thallium-201 |
| Principal use |
Myocardial perfusion SPECT |
| Secondary use |
Selected parathyroid imaging |
| Physical half-life |
Approximately 73 hours |
| Administration |
Intravenous injection |
| FDA status |
Approved diagnostic radiopharmaceutical |
| Drug class |
Small-molecule radioactive diagnostic agent |
| Primary competitors |
Tc-99m sestamibi, Tc-99m tetrofosmin, cardiac PET agents |
| Biosimilar exposure |
None |
| Current patent dependence |
Low to negligible |
What is the FDA regulatory status of thallous chloride Tl-201?
Thallous chloride Tl-201 is an FDA-approved prescription diagnostic product rather than a therapeutic drug. Products are marketed as sterile injectable radiopharmaceuticals, with labeling covering myocardial perfusion imaging and related diagnostic applications.[1]
The product is regulated through the FDA drug approval framework and radioactive-material controls. Commercial suppliers must also comply with applicable state and federal radioactive-material licensing, manufacturing controls, sterility requirements, calibration standards, and distribution restrictions.
The product is commonly billed under HCPCS code A9505, which identifies thallium Tl-201 diagnostic administration on a per-millicurie basis.[3] Reimbursement is therefore linked to imaging utilization and administered radioactivity rather than conventional prescription volume.
What is the Orange Book status of thallous chloride Tl-201?
Thallous chloride Tl-201 is a legacy product with no commercially significant period of remaining new-drug exclusivity. Its market access is not dependent on a current formulation patent or a modern exclusivity period.
The FDA Orange Book remains the relevant source for approved applications, therapeutic-equivalence information, patent listings, and exclusivity data.[4] For a product this old, commercial competition is generally governed by manufacturing capability, supply reliability, hospital purchasing contracts, and regulatory compliance rather than by Orange Book patent barriers.
What patents protect thallous chloride Tl-201?
No active patent estate appears to protect the underlying thallium-201 chloride product in a commercially meaningful way. The active ingredient, imaging use, and core radiopharmaceutical concept date back several decades. Any historical composition, preparation, or use patents would have expired long before the current market period.
Potentially relevant intellectual-property categories include:
| IP category |
Commercial relevance |
| Thallium-201 chloride composition |
Historical only; no meaningful current exclusivity |
| Myocardial perfusion imaging method |
Broad method claims are generally expired or difficult to enforce against routine clinical use |
| Injection formulation |
Limited opportunity for durable exclusivity |
| Isotope production |
Process know-how may remain confidential but is not equivalent to product patent protection |
| Radiochemical purification |
Manufacturing know-how can create operational barriers |
| Packaging and distribution |
Usually protected by trade secrets, quality systems, and contracts |
| Automated imaging protocols |
May be protected by software or device rights, not by the drug itself |
How strong is the thallous chloride Tl-201 patent estate?
The patent estate is weak from a market-exclusivity perspective. The product has no evident active patent moat comparable to a branded therapeutic, complex biologic, or modern drug-delivery system.
The practical barriers are operational:
- Access to qualified thallium-201 production.
- Radiochemical purity and sterility controls.
- Licensed radioactive-material handling.
- Short distribution windows and inventory planning.
- Hospital and nuclear-pharmacy qualification.
- Reliable reimbursement and supply contracts.
These barriers can reduce the number of suppliers without creating legally enforceable exclusivity.
When does thallous chloride Tl-201 lose exclusivity?
Thallous chloride Tl-201 lost meaningful regulatory and patent exclusivity many years ago. There is no commercially relevant upcoming loss-of-exclusivity event comparable to the expiration of a modern branded drug patent.
The product’s current market should be classified as mature and effectively off-patent. Entry risk is therefore determined by whether a supplier can obtain approval, source the isotope, establish compliant manufacturing, and distribute the product at acceptable cost.
| Exclusivity element |
Current assessment |
| New chemical entity exclusivity |
Expired |
| Orphan exclusivity |
Not applicable |
| Pediatric exclusivity |
Not commercially relevant |
| Patent term extension |
Not commercially relevant |
| Active composition patent |
None of material commercial significance identified |
| Formulation patent |
No material current barrier identified |
| Biosimilar exclusivity |
Not applicable |
| Paragraph IV exposure |
Low practical relevance |
Which companies supply or compete with thallous chloride Tl-201?
Commercial supply has historically involved specialized radiopharmaceutical manufacturers and nuclear-pharmacy distributors, including Bracco Diagnostics and other radiopharmaceutical suppliers operating in national or regional markets. Supplier participation can vary by country, product presentation, manufacturing authorization, and isotope availability.
The most important competitive products are not chemically similar generics. They are alternative cardiac imaging agents:
| Product category |
Competitive effect on Tl-201 |
| Tc-99m sestamibi |
Major substitute for myocardial perfusion SPECT |
| Tc-99m tetrofosmin |
Major substitute for myocardial perfusion SPECT |
| Cardiac PET tracers |
Substitute where PET infrastructure is available |
| Stress echocardiography |
Non-radioactive diagnostic alternative |
| Coronary CT angiography |
Competes for selected diagnostic workups |
| Stress cardiac MRI |
Competes in equipped centers |
Technetium-99m agents have shorter half-lives, favorable imaging characteristics, and established hospital workflows. Their use has displaced thallium in many myocardial perfusion protocols. Thallium remains relevant where redistribution imaging, legacy equipment, local protocols, or supply economics support its use.[2,5]
How does thallous chloride Tl-201 compare with Tc-99m sestamibi?
Tc-99m sestamibi generally has the stronger commercial position in routine myocardial perfusion SPECT. It provides lower patient radiation exposure in many protocols, supports broad nuclear-cardiology workflow, and benefits from established supply chains.
Thallium retains technical advantages in redistribution imaging and viability assessment. Those advantages have not offset the broader shift toward technetium-based SPECT and PET.
| Factor |
Tl-201 |
Tc-99m sestamibi |
| Typical role |
Legacy myocardial perfusion and redistribution imaging |
Routine myocardial perfusion SPECT |
| Half-life |
Approximately 73 hours |
Approximately 6 hours |
| Radiation burden |
Generally higher |
Generally lower in common protocols |
| Redistribution |
Strong clinical utility |
More limited |
| Market direction |
Mature to declining |
Larger and more established |
| Supply economics |
Isotope-specific and constrained |
Integrated into wider Tc-99m networks |
| Patent position |
Mature, off-patent |
Mature, off-patent |
What is the financial trajectory for thallous chloride Tl-201?
The financial trajectory is best characterized as mature, low-growth, and structurally pressured. No public issuer separately discloses Tl-201 revenue, gross margin, or unit volume. Radiopharmaceutical manufacturers typically report broader diagnostic or nuclear-medicine segments, making product-level financial reconstruction unavailable from public filings.
Revenue is affected by five variables:
- Number of myocardial perfusion studies using thallium.
- Per-millicurie reimbursement under HCPCS A9505.
- Hospital purchasing and nuclear-pharmacy contracts.
- Isotope production and distribution costs.
- Substitution by Tc-99m and PET agents.
The product has limited ability to increase price through differentiation because it is off-patent and competes with established alternatives. Pricing power is more likely to arise from temporary shortages, regional supplier concentration, or contract renewals than from intellectual property.
What are the main revenue drivers?
Thallium-201 revenue is concentrated in cardiac imaging markets with established SPECT infrastructure. Demand is stronger where:
- Nuclear cardiology remains a major diagnostic service.
- Existing protocols continue to use thallium.
- Tc-99m availability is constrained.
- PET capacity is limited.
- Hospitals maintain legacy equipment and trained personnel.
- Reimbursement supports radiopharmaceutical acquisition and administration costs.
Revenue is weaker where providers have shifted to technetium-based SPECT, PET, coronary CT angiography, or stress MRI.
What are the main cost pressures?
The principal cost pressures are radioactive-isotope production, quality control, specialized shipping, regulatory compliance, and low-volume manufacturing. Unlike conventional injectables, Tl-201 cannot be produced and warehoused through ordinary pharmaceutical channels. Production and distribution require nuclear infrastructure and time-sensitive logistics.
The 73-hour half-life is longer than that of Tc-99m, which can support broader shipping windows, but it also contributes to higher radiation exposure and less favorable clinical positioning. Reactor, cyclotron, target-material, and transportation disruptions can affect supply economics across the radiopharmaceutical market.[6]
What manufacturing and intellectual-property barriers affect Tl-201?
Manufacturing barriers are more significant than patent barriers. A supplier must control the isotope-production process, radionuclidic purity, radiochemical purity, sterility, endotoxin levels, activity calibration, container closure, and release testing.
The key commercial barrier is scale. A small supplier may obtain regulatory approval but still struggle to compete against an established nuclear-pharmacy network with regional distribution, hospital contracts, and validated quality systems.
Trade secrets may protect isotope-production methods, purification conditions, automated filling, dose calibration, or logistics systems. Those protections can support a supplier’s position but do not prevent a technically capable competitor from entering the market.
Are there Paragraph IV challenges or patent litigation involving Tl-201?
Paragraph IV litigation is not a central market issue for thallous chloride Tl-201. The product is a legacy diagnostic agent without a commercially important active patent estate. Publicly visible pharmaceutical litigation does not indicate a current, material patent dispute that would delay generic or alternative supplier entry.
Any dispute affecting supply is more likely to involve manufacturing compliance, product quality, procurement contracts, radioactive-material licensing, or distribution arrangements than patent infringement.
Are there biosimilar risks for thallous chloride Tl-201?
Biosimilar risk is not applicable. Thallous chloride Tl-201 is a small-molecule radiopharmaceutical and is not a biologic. Competitive risk comes from generic-equivalent radiopharmaceutical supply and therapeutic substitution by other imaging modalities.
The relevant competitive threats are:
- Additional Tl-201 suppliers.
- Tc-99m myocardial perfusion agents.
- Cardiac PET.
- Non-nuclear imaging modalities.
- Lower utilization of stress perfusion imaging in selected patient populations.
What licensing deals and settlements affect Tl-201?
No major publicly disclosed licensing transaction or patent settlement is associated with thallous chloride Tl-201 as a standalone product. Commercial arrangements are more likely to involve supply contracts, regional distribution agreements, nuclear-pharmacy services, or bundled radiopharmaceutical purchasing.
There is no known settlement framework comparable to those used for high-revenue branded therapies facing Paragraph IV entry. The commercial market is therefore more sensitive to supply continuity and procurement terms than to settlement timing.
What generic launch scenarios exist for thallous chloride Tl-201?
A new supplier could enter through one of three practical routes:
- Obtain approval for a Tl-201 injectable product and compete directly on supply and price.
- Acquire or partner with an established radiopharmaceutical manufacturer.
- Enter through regional nuclear-pharmacy distribution where national-scale production is not required.
The most realistic launch scenario is incremental regional entry rather than a major national launch. The addressable market is constrained by substitution and clinical decline, while manufacturing and distribution costs remain high.
A new entrant would face:
- Limited growth in total myocardial perfusion demand.
- Strong incumbent relationships with hospitals.
- Qualification requirements for nuclear pharmacies.
- Dependence on isotope availability.
- Limited patent protection to support premium pricing.
- Clinical preference for Tc-99m and PET in many settings.
What is the geographic coverage of the Tl-201 market?
The market is strongest in the United States, Japan, Europe, and other countries with established nuclear-medicine infrastructure. Geographic demand depends on cardiac imaging practice, regulatory approvals, nuclear-pharmacy networks, isotope production, reimbursement, and hospital equipment.
The United States has a mature reimbursement and coding framework, including HCPCS A9505. European and Asian markets can differ substantially in radiopharmaceutical procurement, hospital ownership, reimbursement, and nuclear-material licensing.
Supply is inherently regional because radioactive products require specialized transport and activity decays over time. This reduces the efficiency of global inventory strategies and makes local manufacturing or distribution partnerships commercially important.
Key Takeaways
- Thallous chloride Tl-201 is an FDA-approved, mature diagnostic radiopharmaceutical used mainly for myocardial perfusion imaging.
- The product has no meaningful remaining patent or regulatory exclusivity.
- Orange Book patent protection is not the principal determinant of market access.
- No biosimilar issue applies; competition comes from generic-equivalent supply and alternative imaging agents.
- Tc-99m sestamibi and Tc-99m tetrofosmin are the most important SPECT substitutes.
- Cardiac PET, stress MRI, stress echocardiography, and coronary CT angiography create additional substitution pressure.
- No public company discloses standalone Tl-201 revenue, so financial analysis depends on utilization, reimbursement, and supplier economics.
- The financial trajectory is mature to declining, with limited pricing power and high sensitivity to isotope supply and hospital contracts.
- Manufacturing, radioactive-material licensing, quality systems, and distribution are stronger barriers than patents.
- No material current Paragraph IV litigation or patent settlement is associated with the product.
FAQs
Is thallous chloride Tl-201 still commercially available?
Yes. Availability depends on supplier approvals, regional nuclear-pharmacy networks, isotope production, and local hospital demand. It is a legacy product with narrower use than technetium-based cardiac agents.
Is Tl-201 used for cancer treatment?
No. Thallous chloride Tl-201 is used as a diagnostic imaging agent. It is not a therapeutic oncology radiopharmaceutical.
Does thallium-201 have a longer half-life than technetium-99m?
Yes. Thallium-201 has a physical half-life of about 73 hours, while technetium-99m has a half-life of about six hours. The difference affects imaging protocols, radiation exposure, logistics, and clinical preference.
What HCPCS code is used for thallium Tl-201?
CMS identifies thallium Tl-201 under HCPCS A9505, generally billed according to administered millicurie quantity.[3]
Can a new manufacturer obtain premium pricing for Tl-201?
Premium pricing would generally require a supply advantage, regional scarcity, validated logistics, or a differentiated service model. Patent protection is unlikely to support premium pricing because the product is an old, off-patent radiopharmaceutical.
References
-
U.S. Food and Drug Administration. (n.d.). Thallous chloride Tl-201 injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
International Atomic Energy Agency. (2019). Nuclear medicine resources manual. IAEA. https://www.iaea.org/
-
Centers for Medicare & Medicaid Services. (2025). Healthcare Common Procedure Coding System (HCPCS) quarterly update. https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
American Society of Nuclear Cardiology. (2018). Single-photon emission computed tomography myocardial perfusion imaging guidelines. Journal of Nuclear Cardiology. https://www.asnc.org/
-
U.S. Nuclear Regulatory Commission. (2024). Medical use of radioactive materials and transportation requirements. https://www.nrc.gov/reading-rm/doc-collections/fact-sheets/med-use-of-radioactive-materials.html
